Indo-Bangla Pharmaceuticals Limited

DSE:IBP Stock Report

Market Cap: ৳1.1b

Indo-Bangla Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

A. F. M. Huq

Chief executive officer

৳4.0m

Total compensation

CEO salary percentagen/a
CEO tenure10.5yrs
CEO ownership16.1%
Management average tenureno data
Board average tenure10.5yrs

Recent management updates

Recent updates


CEO

A. F. M. Huq (49 yo)

10.5yrs

Tenure

৳3,970,000

Compensation

Mr. A. F. M. Anowarul Huq serves as Managing Director and Director at Indo-Bangla Pharmaceuticals Limited since June 18, 2014.


Board Members

NamePositionTenureCompensationOwnership
A. F. M. Huq
MD & Director10.5yrs৳3.97m16.05%
BDT 173.5m
Md. Anam
Directorless than a year৳10.00kno data
Aziza Yeasmin
Chairperson10.5yrs৳40.00k2.11%
BDT 22.8m
Hafiza Yeasmin
Director10.5yrs৳100.00k2.11%
BDT 22.8m
A. K. M. Rashid
Independent Director1.3yrsno datano data

10.5yrs

Average Tenure

50yo

Average Age

Experienced Board: IBP's board of directors are seasoned and experienced ( 10.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 03:33
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Indo-Bangla Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution